Home » Market News » DirectorsTalk Highlights » Frontier IP Amprologix wins DHSC backing for new antibiotic
Frontier IP Group Plc

Frontier IP Amprologix wins DHSC backing for new antibiotic

Neil Crabb, chief executive officer of Frontier IP, said“We are delighted the SBRI is backing this programme, which validates our approach to IP commercialisation. Through Amprologix and Professor Upton’s ground-breaking science, there is huge potential to prove the efficacy of epidermicin and identify further new antibiotics that can be manufactured at scale.”

Frontier IP (LON:FIPP), a specialist in commercialising university intellectual property, today announced portfolio company Amprologix has won a contract worth £1.2 million funded by the UK Department for Health and Social Care to accelerate development and scale up its lead antibiotic candidate to tackle antimicrobial resistant MRSA and related superbugs.

The contract from the Small Business Research Initiative (“SBRI”), administered by Innovate UK, will be used to make the Company’s epidermicin NI01 antibiotic ready for phase 1 human clinical trials during early 2021.

Epidermicin NI01 is the lead candidate in a new family of epidermicin-based antibiotics being developed by Amprologix, a spin out from the University of Plymouth. Amprologix was established last year to commercialise the work of Mathew Upton, Professor of Medical Microbiology at the University’s Institute of Translational and Stratified Medicine.

The Company has already secured industry involvement. Ingenza, a leader in industrial biotechnology and synthetic biology, is also a shareholder, and Frontier IP holds a 10 per cent stake in return for providing a range of commercialisation services. Amprologix’s first product is expected to be a nasal cream containing NI01 to prevent MRSA infections.

For the project, Professor Upton will optimise the formulation of epidermicin and conduct a pre-clinical toxicology evaluation. Amprologix will license optimised microbial based production technology from Ingenza’s biologics manufacturing platform to produce the new antibiotics at scale.

Professor Upton is also working separately with Ingenza, IBM and the National Physical Laboratory, using Artificial Intelligence to create a portfolio of novel, adaptable antibiotic candidates for future exploitation.

Epidermicin is derived from bacteria found on human skin. Work conducted to date shows a single dose was as effective as six doses of the current gold standard treatment in a relevant model of MRSA infection. Antimicrobial-resistant bacteria kill more than 25,000 people a year in Europe, while MRSA was named in 2017 as a “high priority” target for antibiotic research by the World Health Organisation.

Professor Upton initially developed the patented technology while at The University of Manchester, which owns an equity share of the business through UMI3 Ltd, its IP commercialisation arm.

Professor Mathew Upton, chief scientific officer at Amprologix, said: “I feel very strongly that epidermicin has excellent potential for use in nasal decolonisation to prevent skin and wound infections, like those caused by MRSA. Development of NI01 could have immense benefits for patients, so I’m genuinely excited about this work and generating the data needed to enter phase 1 trials.”

Dr Gordon Barker, chief executive officer of Amprologix, said “Despite the urgent need for new antibiotics and new approaches to treatment, it remains extremely difficult to fund new drug discovery ventures in this space. The government-backed SBRI programme is a world-leading scheme to address this market failure and we’re really grateful for their support, which will accelerate the development of next generation life-saving medicines like NI01.”

Dr Ian Fotheringham, managing director of Ingenza, said: “We are developing advanced biologics manufacturing technologies to address exactly this kind of critical unmet therapeutic need. Our platform will underpin the future success of this exciting new family of potent and selective antimicrobials.”

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.